HU

Hugel, Inc.

Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.

145020 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
강원특별자치도 춘천시 동내면 거두단지1길 23 -, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hugel, Inc. is a global biopharmaceutical company specializing in the medical aesthetics and therapeutics market. The company develops, manufactures, and sells a range of products, including its flagship botulinum toxin, hyaluronic acid (HA) fillers, skin boosters, and cosmetic threads. Recognized for its advanced technology, Hugel is a leading provider in the aesthetics field, having expanded its presence from its base in South Korea to major international markets such as the USA, Europe, and China. The company focuses on creating value in medical aesthetics by providing high-quality, scientifically-backed solutions for medical professionals and consumers.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Hugel, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-15 00:00
Board/Management Information
대표집행임원변경
Korean 12.6 KB
2025-09-15 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-09-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.1 KB
2025-08-29 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 8.6 KB
2025-08-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-14 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.5 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB

Automate Your Workflow. Get a real-time feed of all Hugel, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hugel, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.